Targets › RH5
1 program from 1 company in 2 trials: 1 Phase 2, 1 Phase 1; Infectious disease; next expected readout Mar 2027.
Open in Phaseline: the race on RH5, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University of Oxford | RH5.1 Soluble RIPR EGF-CyRPA fusion protein vaccine | RH5, RIPR, CYRPA | Phase 2 | Malaria,Falciparum | Mar 2027 |
Malaria,Falciparum (2)
protein or peptide (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.